Moderna Inc is trading 5% up at $51.61, continuing a multi-day rally after the company presented highly positive long-term data for its personalized cancer vaccine.
- At the ASCO 2026 meeting on June 1, Moderna and partner Merck announced that their vaccine, combined with Keytruda, reduced the risk of recurrence or death by 49% in high-risk melanoma patients over a 5-year period.
- The stock is also reacting to an expanded partnership with CEPI for an Ebola vaccine candidate and investor anticipation ahead of the Goldman Sachs Global Healthcare Conference on June 9.